V ascular complications related to arterial access are common causes of morbidity, mortality, and cost in patients undergoing percutaneous coronary intervention (PCI). 1,2 Multiple strategies have been used to decrease the risk of bleeding and vascular access site complications at the time of PCI. 3 These strategies have focused on several areas in the care of patients at the time of PCI, including the choice of arterial access site for the procedure, the choice of optimal pharmacological therapy during PCI, and the decision to use arterial closure devices (ACDs) for patients when a transfemoral route is chosen. Although transradial PCI is likely the most effective mechanism for preventing access site complications, 4 only a minority of patients in the United States receive PCI via this route at present. 5 The role of ACDs in patients having PCI is controversial. A large number of previous studies have evaluated the efficacy of ACDs in preventing complications in patients undergoing PCI. Some of the initial randomized trials were small, underpowered, and do not reflect current PCI practice. The largest Background-Bleeding is associated with poor outcomes after percutaneous coronary intervention (PCI). Although arterial closure devices (ACDs) are widely used in clinical practice, whether they are effective in reducing bleeding complications during transfemoral PCI is uncertain. The objective of this study was to evaluate the effectiveness of ACDs for the prevention of vascular access site complications in patients undergoing transfemoral PCI using an instrumental variable approach. Methods and Results-We performed a retrospective analysis of the CathPCI Registry from 2009 to 2013 at 1470 sites across the United States. Variation in the proportion of ACDs used by each individual physician operator was used as an instrumental variable to address potential confounding. A 2-stage instrumental variable analysis was used as the primary approach. The main outcome measure was vascular access site complications, and nonaccess site bleeding was used as a falsification end point (negative control) to evaluate for potential confounding. A total of 1 053 155 ACDs were used during 2 056 585 PCIs during the study period. The vascular access site complication rate was 1.5%. In the instrumental variable analysis, the use of ACDs was associated with a 0.40% absolute risk reduction in vascular access site complications (95% confidence interval, 0.31-0.42; number needed to treat=250). Absolute differences in nonaccess site bleeding were negligible (risk difference, 0.04%; 95% confidence interval, 0.01-0.07), suggesting acceptable control of confounding in the comparison. Conclusions-ACDs are associated with a modest reduction in major bleeding after PCI. The number needed to treat with ACDs to prevent 1 major bleeding event is high. (Circ Cardiovasc Interv. 2016;9:e003464.
Arterial Closure Devices in PCI meta-analysis on the subject raised concerns that ACDs may be associated with an increased risk in complications. 6 The most recent randomized trial found noninferiority between the use of ACDs and manual compression in patients undergoing diagnostic coronary angiography, some of whom also had PCI. 7 Large observational studies have also evaluated the efficacy of ACDs 5, [8] [9] [10] [11] [12] [13] and have generally found reductions in bleeding or vascular complications associated with their use. However, because the selection of ACD use at a patient level is often determined by characteristics that are rarely included in detailed clinical registries, such as the location and quality of the arterial puncture and the severity of atherosclerotic disease or calcification in the accessed femoral artery, there is reason to think that these studies may be confounded.
Therefore, we sought to determine whether ACDs are effective in preventing vascular access site complications with PCI using an instrumental variable approach, which may be less susceptible to confounding by unmeasured variables. 14 Our hypothesis was that ACDs would not be associated with a clinically meaningful reduction in in-hospital vascular access complications after PCI.
Methods

Data Set and Patient Selection
The National Cardiovascular Data Registry's CathPCI Registry, a partnership between the American College of Cardiology and the Society for Cardiovascular Angiography and Interventions, is a national quality improvement program that includes in-hospital data in patients undergoing cardiac catheterization and PCI procedures and has been previously described. 15, 16 The analyses here used version 4 of the CathPCI Registry, which contained data from 2 492 770 hospital admissions for PCI from July 1, 2009, until September 30, 2013. A full description of the data elements in the version 4 of the CathPCI Registry is available at https:// www.ncdr.com/WebNCDR/cathpci/home/datacollection. Patients were excluded from the analysis if they underwent PCI via a non-femoral approach, if they underwent >1 PCI during the hospital admission, if the PCI procedure was classified as a salvage procedure, if the PCI was performed with an intra-aortic balloon pump or other form of mechanical circulatory support, or if the PCI was performed by a physician operator who had performed <25 PCIs in the CathPCI Registry during the study period. Waiver of written informed consent and authorization for this study was granted by Chesapeake Research Review Incorporated.
Study Outcomes
The primary outcome variables for the analysis were vascular access site complications, which were defined as a composite of bleeding at the access site with associated transfusion, hematoma >5 cm at the access site, and retroperitoneal bleeding post PCI. In order to ensure the absence of confounding in our main comparison, we prespecified the use of a negative control, or falsification, hypothesis by assessing the effect of ACDs on nonaccess site bleeding. 17 Nonaccess site bleeding was defined as gastrointestinal bleeding, genitourinary bleeding, cardiac tamponade, or hemorrhagic stroke post PCI. Such end points would not be expected to be influenced in a causal manner by the use of ACDs such that any differences in these outcomes would likely be the result of residual confounding. We also analyzed secondary end points, including the individual outcomes comprising the composite end point, National Cardiovascular Data Registry major bleeding, 18 in-hospital mortality, and postprocedure length of stay. National Cardiovascular Data Registry major bleeding was defined as any of the following occurring before hospital discharge: arterial access site bleeding (defined as external bleeding at access site or a hematoma >10 cm for femoral access, >5 cm for brachial access, or >2 cm for radial access); retroperitoneal, gastrointestinal, or genitourinary bleeding; intracranial hemorrhage; cardiac tamponade; postprocedure hemoglobin decrease of 3 g/ dL in patients with a preprocedure hemoglobin level ≤16 g/dL; or postprocedure non-bypass surgery-related blood transfusion for patients with a preprocedure hemoglobin level ≥8 g/dL.
Patient and Procedural Characteristics
We identified patient and procedural characteristics among patients treated with ACDs and those treated without ACDs at the time of the index PCI procedure. These variables included sociodemographic characteristics (age, sex, race, and region), medical history (diabetes mellitus, hypertension, hyperlipidemia, smoking status, previous PCI, previous myocardial infarction, previous coronary artery bypass graft surgery, congestive heart failure, peripheral vascular disease, cerebrovascular disease, chronic lung disease, atrial fibrillation, history of cancer, history of gastrointestinal bleeding, chronic kidney disease, hemodialysis, and history of lung disease), and presentation characteristics (ST-segmentelevation myocardial infarction versus non-ST-segment-elevation myocardial infarction versus other presentation, duration of acute coronary syndrome, and presentation with shock). Periprocedural antiplatelet use and anticoagulant use were also evaluated. Factors related to the physician operator, including whether they practiced at a teaching hospital and the annual operator volume of PCIs reported in the CathPCI data set, were also evaluated. These variables were used for statistical adjustment for all models subsequently described.
Statistical Analysis
We used an instrumental variable approach to attempt to account for selection bias and unmeasured confounding as many PCI procedural variables and treatment decisions are influenced by characteristics that are poorly ascertained in observational analyses. 19 Valid instrumental variables or instruments are causally related to the exposure of interest but unrelated to the outcome of interest except through the pathway of the exposure itself. Thus, by exploiting the natural randomness in treatment assignment through an instrumental variable approach, we are able to reduce the influence of bias in the analysis. We used the proportion of ACD use of PCI-performing physicians as our instrumental variable. This approach, which takes advantage of physician practice variation, has been referred to as a
WHAT IS KNOWN
• The effectiveness of arterial closure devices to reduce bleeding complications after transfemoral percutaneous coronary intervention is uncertain.
• Randomized trials comparing arterial closure devices to manual compression in patients undergoing percutaneous coronary intervention have been inconclusive.
WHAT THE STUDY ADDS
• We used operator variation in preference of arterial closure devices after transfemoral percutaneous coronary intervention as an instrumental variable to assess the effectiveness of these devices at reducing arterial access site bleeding compared with manual compression.
• We showed that the use of arterial closure devices was associated with a modest but significant reduction in access site bleeding.
• This analysis highlights the use of an instrumental variable approach as a method to control for unmeasured confounding in nonrandomized data.
preference-based instrumental variable and has been previously described. 20 Specifically, transfemoral PCIs performed by operators with <20% ACD use (low) or >80% ACD use (high) were identified. We included only low and high ACD users to take advantage of operators who were consistent in their choice to use or not use ACDs.
To perform the instrumental analysis, we used a standardized approach, the 2-stage least squares linear regression method, which produces adjusted estimates of treatment effect on an absolute rather than a relative scale. 21, 22 We prespecified several analyses to confirm the adequacy of our selected instrumental variable before examining the primary outcomes. First, we examined the distribution in operator propensity to use ACDs by constructing a histogram of the proportion of PCIs involving ACDs for each operator. After confirming adequate variation to support the approach, we then calculated standardized differences for a wide range of patient factors and procedural factors between those patients treated by low-ACD use operators or high-ACD use operators. Standardized differences were used to compare differences between groups instead of P values as these measures are able to calculate the effect size between groups independent of sample size. Although standardized differences were initially developed in the context of comparing the mean of a continuous variable between 2 groups, this measure has also been used to compare binary and categorical variables. 23 Standardized differences <10% were considered significant as previously described. 23 Two-stage least squares regression was then performed using the SAS procedure PROC SYSLIN 24 to assess the adjusted absolute risk reduction in vascular access site complications with ACDs. This method relied on building 2 sequential linear regression models with treatment of the dependent variable in the second-stage linear model as a binary variable. 22 In the first-stage model, we regressed the predicted use of an ACD on our instrument, the proportion of PCI cases with ACD use by the individual physician operator, adjusting for all covariates described above. In the second-stage model, we regressed our outcome variable on the predicted value of receiving an ACD as estimated from the firststage model, in addition to adjusting for all of the covariates described above. The absolute differences between those treated with ACDs and those not treated with ACDs were estimated based on the coefficient of the instrumental variable in the second regression model. Robust SEs were estimated for all analyses, and P values <0.05 were considered significant. Analyses were performed using SAS version 9.3 (Cary, NC).
Evaluation of the Instrumental Variable Assumptions
A valid instrument requires several assumptions to be justified. 21 First, the instrument should strongly predict the exposure of interest. In this case, the assumption is that patients treated by high-ACD use operators were more likely to receive an ACD during the index PCI. A second assumption is that the instrument affects the outcome only through its association with the primary predictor of interest, a fundamentally untestable assumption. A third assumption is that the instrumental variable should effectively randomize patients such that patients should be similar with respect to measured and unmeasured factors across levels of the instrument.
Results
The patient population used for the analysis is shown in Figure 1 . A total of 1 053 155 ACDs were used during 2 056 585 PCIs during the study period. Patients who did not receive an ACD had higher rates of peripheral arterial disease and were more likely to present with severe symptoms of heart failure. Otherwise, patients and procedural characteristics were overall similar between patients who received an ACD compared with those who did not ( Table 1) .
Data from 1 121 714 patients with PCI performed by 4331 physicians at 1375 centers were analyzed when assessing those patients treated by high-and low-ACD use operators. The distribution of the proportion of ACD use by physician operator is shown in Figure 2 . There were 2035 low-ACD use operators and 2296 high-ACD use operators. These 4331 operators represent 55.3% of the total number of physician operators in the study sample. The clinical and procedural characteristics of patients treated by high-ACD use operators and low-ACD use operators are shown in Tables 2 and 3 . Among those treated by low-ACD use operators, 94.1% of patients received no ACD, 3.9% received a sealant device, 0.9% received a suture device, and 0.6% received a patch-based device. Among those patients treated by the high-ACD use operators, 9.6% of patients received no ACD, 60.5% of patients received a sealant device, 17.7% of patients received a suture-based device, and 5.8% of patients received a patch-based device.
Vascular access site complications occurred in 1.5% of patients overall. CathPCI-defined major bleeding occurred in 4.6% of patients. Nonaccess site bleeding occurred in 0.4% of patients. Among those treated by high-ACD use operators, vascular access site complications occurred in 1.6%, major bleeding occurred in 3.6%, and nonaccess site bleeding occurred in 0.4%. Among those treated by low-ACD use operators, vascular access site complications occurred in 1.3%, major bleeding occurred in 5.7%, and nonaccess site bleeding occurred in 0.3%. Patient and procedural characteristics for PCIs performed by high-versus low-use ACD operators were similar. Standardized differences were <10% in 42 of 46 variables, and <15% in all 46 clinical, demographic, and procedural factors evaluated in the 2 populations. High-ACD use physicians and low-ACD use physicians had similar annual PCI volumes and were similarly likely to perform procedures in teaching hospitals ( Table 3 ).
In the instrumental variable analysis, physician operator was highly predictive of actual ACD use ( Table 2 ). High-ACD use operators used ACDs in 90.3% of PCIs, whereas low-ACD use operators used ACDs in 5.9% of PCIs. The use of ACDs was associated with a 0.36% absolute risk reduction in vascular access site complications (95% confidence interval [CI]: 0.31-0.42; number needed to treat=250; Table 4 ). Absolute differences in nonaccess site bleeding were negligible (risk difference, 0.04%; 95% CI, 0.01-0.07), suggesting acceptable control of confounding in the comparison. The use of ACDs was associated with a 0.73% absolute risk reduction in major bleeding (95% CI, 0.64-0.82; number needed to treat=137). ACD use was also associated with a small reduction in post-PCI length of stay (0.12 days; 95% CI, 0.10-0.13). ACD use was not associated with a reduction in-hospital mortality (0.03%; 95% CI, −0.07 to 0.04).
Discussion
We found that the use of ACDs is associated with a small but significant reduction in vascular access site complications compared with manual compression in patients undergoing PCI. There was wide variation in the physician use of such devices although this predilection did not seem to be related to measured patient or physician factors. These findings highlight the lack of strong evidence supporting the use of such devices, creating the preconditions for unexplained variation in care. Exploiting this variation through the instrumental variable approach allowed for the estimation of the effect of ACD use on important bleeding and vascular complications that was less susceptible to confounding by traditional regression approaches.
In this analysis, ACD use corresponded to an absolute 0.36% reduction in access site bleeding. As the absolute difference in our falsification end point, nonaccess site bleeding, between treatment strategies was small and not clinically meaningful, we think that the reduction in access site bleeding in the primary analysis is most likely attributable to ACD NYHA class (among heart failure within 2 wk) 15 use rather than residual confounding by unmeasured variables. Although our findings suggest that ACDs are associated with some clinical benefit, we conclude that that benefit is relatively small in terms of preventing complications. We calculated that 250 patients need to be treated with ACDs to prevent 1 vascular access site complication. Given their relatively modest cost in the scheme of an overall PCI, patient and physician convenience may be enough to justify their use. However, we also acknowledge that given the low rates of bleeding and vascular complications, even interventions that are highly efficacious would still have a relatively large cost per complication prevented. A similar critique has been made of the recent Instrumental Sealing of Arterial Puncture Site Closure Device Versus Manual Compression Trial (ISAR-CLOSURE), 7,25 which compared ACDs against manual compression in patients undergoing coronary angiography without PCI. Several previous authors in this field have called ACDs bleeding avoidance strategies that can be used systematically as a way to reduce bleeding or access site complications during transfemoral PCI. 3, 5, 9, 26, 27 For example, Marso et al 9 found a 0.7% reduction in periprocedural bleeding with the use of an ACD compared with manual compression after transfemoral PCI. We found lower reductions in bleeding, perhaps because of differences in methodology (eg, less susceptibility to confounding), end point definitions and study time periods. Regardless, these data suggest that although ACDs can have a role in preventing complications, the role is likely modest when seen in the totality of the care of the patient with coronary artery disease undergoing PCI. Other interventions, including transradial PCI or choices in antithrombotic or antiplatelet agents, likely have a much larger effect in preventing bleeding or access site complications overall.
The analyses presented here are based on an instrumental variable approach to causal inference. Instrumental variable analyses exploit situations where some degree of randomness affects how patients are selected for a treatment. 14 In this case, the variation in likelihood of using ACDs across physicians was used as the instrumental variable. The observation that patient characteristics among high-versus low-ACD use operators were similar supports the validity of using this approach. We additionally used a falsification end point in the analysis, namely nonaccess site bleeding, which would not be expected to be influenced by ACD use. We do note that the P value for nonaccess site bleeding was nominally significant, secondary to the extremely large sample size and the inability of any observational study to completely eliminate potential confounding. However, we are reassured that the actual difference (0.04%) was unlikely to be clinically meaningful. In contrast, we have previously shown that the use of nonaccess site bleeding could effectively show that comparisons of radial and femoral access among patients with PCI are susceptible to confounding. 17 Beyond the validity of the chosen instrumental variable, our study is limited in several additional ways. Our study was not designed to detect differences in the effectiveness of individual ACDs as the instrumental variable approach is not well suited to examine subgroups. Although our results give an average overall effect of ACD use, the effectiveness of some ACDs may be different from others. We also did not take into account the learning curve with these devices. 28 In addition, we are limited by the accuracy of the event ascertainment in our data set. End points in this data set are not individually adjudicated, and both under-reporting and over-reporting are possible. Finally, we are limited by the fact that the data set does not capture all of the clinical factors that are used in routine practice to determine whether use of a particular ACD is appropriate, as we did not have access to femoral angiograms, or their interpretation, nor did we have access to historical factors, such as whether an ACD was used during a previous angiogram or PCI.
Conclusions
In summary, in this large, contemporary, real-world PCI registry, significant variation in use of ACDs existed among interventional cardiologists performing transfemoral PCIs. By exploiting this randomness of operator preference for ACD use during PCI through an instrumental variable approach that also used a falsification end point, we demonstrated that use of these devices was associated with a modest but significant reduction in vascular access site complications compared with manual compression. A detailed cost-benefit analysis may be helpful in informing future treatment decisions. 
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